1. Volume 59, Issue 4, Pages 885-888 (October 2013)
ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: A race for an interferon-free regimen to cure HCV infection 
Tarik Asselah 
Journal of Hepatology 
Volume 59, Issue 4, Pages (October 2013)
DOI: /j.jhep
Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

2. Fig. 1
Trial designs and results of studies with ABT-333 based regimen. (A) Phase 2a, multicenter, open-label, trial design [2]. All patients received ABT-333 (400mg twice daily) and ribavirin (1000–1200mg per day) and one of two daily doses of ABT-450/r. Groups 1 and 2 included previously untreated patients; group 1 received 250mg of ABT-450 and 100mg of ritonavir, and group 2 received 150mg and 100mg, respectively. Group 3, which included patients who had had a null (n=7) or partial response (n=10) to previous therapy with PegIFN/ribavirin, received daily doses of 150mg of ABT-450 and 100mg of ritonavir. ABT-450, NS3 protease inhibitor, boosted with ritonavir (ABT-450/r); ABT-333, non-nucleoside NS5B polymerase inhibitor. (B) Phase 2a, multicenter, open-label, trial results [2]. A total of 17 of the 19 patients in group 1 (89%) and 11 of the 14 in group 2 (79%) had an extended rapid virologic response; an SVR 12weeks after the end of treatment was achieved in 95% and 93% of the patients, respectively. In group 3, 10 of 17 patients (59%) had an extended rapid virologic response, and 8 (47%) had an SVR 12weeks after therapy; 6 patients had virologic breakthrough, and 3 had a relapse. HCV RNA<LDQTD or TND (<25IU/ml); eRVR=extended rapid virological response defined as undetectable HCV RNA from week 4 through week 12.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

3. Fig. 2
Aviator study. (A) Trial design [3]. This phase 2b study assesses the safety and efficacy of ABT-450/r (dosed 100/100mg to 200/100mg QD), ABT-267 (25mg QD), ABT-333 (400mg BID), and ribavirin in non-cirrhotic treatment-naïve patients and prior PegIFN/ribavirin null responders for 8, 12 or 24weeks. ABT-450, NS3 protease inhibitor, boosted with ritonavir (ABT-450/r); ABT-267, NS5A inhibitor; ABT-333, non-nucleoside NS5B polymerase inhibitor. (B) Results from the Aviator study [3]. SVR in treatment-naїve genotype 1 (GT1) patients and in GT1 null responder patients.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2013 European Association for the Study of the Liver Terms and Conditions